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ABSTRACT

The invention provides a novel method of administer

ing narcotic antagonists, narcotic analgesics and related
compounds, and novel dosage forms containing those
compounds which are adapted for nasal administration.
The nasal dosage forms disclosed include solutions,

suspensions, gels and ointments. Especially preferred
compounds which can be advantageously administered
in accordance with the invention include naloxone,

naltrexone, nalbuphine, levorphanol, buprenorphine,
butorphanol, A9-tetrahydrocannabin0l (THC), can
nabidiol (CBD) and levonantradol.
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1

METHOD OF ADMINISTERING NARCOTIC
ANTAGONISTS AND ANALGESICS AND NOVEL
DOSAGE FORMS CONTAINING SAME

Pharmac. (1977), 60, 537-545; Jasinski et al, Arch. Gen.
Psychiatry, Vol. 35, April 1978, 501-516; Mello et al,
Science, Vol. 207, Feb. 8, 1980, 657-659.

BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a novel method of

Virtually all of the members of the groups of mor

phine analogues discussed supra are well-absorbed by
injection, but are rarely used orally because of inef?
cient and variable absorption by that route. The low
effectiveness of naloxone when taken orally has been

administering narcotic antagonists, narcotic analgesics
and related compounds, and to novel dosage forms
containing such compounds adapted for nasal adminis
tration.

‘

2. Background Art
Morphine, which has the structural formula
N-Cl-Ig

>

2

pendence potential, as well as its potent narcotic .antag
onist and analgesic activity. See Cowan et al, Br. J.

attributed to the rapid and almost total formation of a

less activemetabolite in the ?rst hepatic transit. See
Fishman et al, J. Pharmacol. Exp. Ther. 187, 575-580
(1973). Also Berkowitz et al, J. Pharmacol. Exp. Ther.
195, 499-504, and the references cited therein.
Yet other structural modi?cations of the morphine
molecule have resulted in codeine and its analogues;
methadone and related compounds; and meperidine and
20 related compounds such as profadol. Also see, gener

ally, Pharmacological Basis of Therapeutics, ed. Good

' HO

O

man and Gilman, sixth edition, Chapter 22, “Opioid
Analgesics and Antagonists”, by Jaffe and Martin, pp.
494-534 (MACMILLAN PUBLISHING CO., INC.,

on

25

is a potent narcotic analgesic which is principally used
to relieve pain; it is also used in the dyspnea of heart
failure, in pulmonary edema and cough, as a sedative

New York, 1980); Cutting’s Handbook of Pharmacology,
sixth edition, ed. T. Z. Czaky, M.D., Appleton-Cen
tury-Crofts/New York, Chapter 50, pp. 551-571.

Recent studies of THC, or A9-tetrahydrocannabinol,
which is the active ingredient in marijuana, or its deriv
paragoric). Morphine causes both depression and stimu 30 atives (e.g. CBD or cannabidiol, and levonantradol)
suggest that these compounds are potentially useful in a
lation in the central nervous system and the gut, its most

and in the control of diarrhea (chiefly in the form of

wide varietyvof therapeutic areas, such as in the preven
tion of narcotic withdrawal symptoms and as antiemet

signi?cant actions being analgesia, hypnosis, respiratory
depression, smooth muscle spasm, nausea, vomiting and

circulatory and other effects (especially miosis). The
drug is well-absorbed by injection, but absorption via

ics, particularly in the treatment of cancer patients un
35

dergoing chemotherapy. Unfortunately, oral adminis
tration has been found to be much less effective than

the oral route is inefficient and variable, probably be
cause of metabolismiinthe liver, chie?y by conjugation

intramuscular injection. See, Medical News, Monday,

with glucuronic acid. Abuse leads to habituation or
addiction.
The morphine molecule has been subjected to a vari
ety of structural modi?cations in efforts to enhance

the various therapeutic uses of THC and its derivatives.

selected properties and/or to deemphasize others, as
well as to produce-drugs which actually antagonize the
effects of morphine and other opioid analgesics. Such

‘In view of the foregoing, it is apparent that a serious
need exists for the improved delivery of narcotic antag

Jan. 19, 1981, page 3, for a more detailed discussion of
SUMMARY OF THE INVENTION

onists‘, narcotic analgesics and related compounds

efforts have led to the development of a variety of 45 which are not well-absorbed orally. Thus, it is an object
classes of chemical compounds, such as the class of
of the present invention to provide novel dosage forms
morphine analogues whose structures are very closely
and a novel method of administering morphine or an
allied to that of morphine, retaining both the phenolic
analogue thereof bearing at least one phenolic hydroxyl
OH and the N-methyl substituent of morphine, such as
substituent and having narcotic analgesic, antagonist or

apomorphine, levorphanol and oxymorphone, and

which as a group have strong analgesic, respiratory

depressant and smooth muscle stimulant activity but
which also are highly addicting. Retention of the phe
nolic hydroxyl while replacing the methyl on the nitro
gen atom with a larger alkyl or similar side-chain has

afforded both morphine analogues which are relatively

50

agonist-antagonist activity, or A9-tetrahydrocannabino1
or a pharmacologically active analogue thereof bearing
at least one phenolic hydroxyl substituent, which will

provide greatly enhanced bioavailability as compared
to oral administration, while at the same time providing
- relative ease of administration when compared to intra

muscular, subcutaneous or intravenous injection. This
object is achieved by nasal administration of morphine,
and‘are used in the treatment of narcotic-induced respi
A9-tetrahydrocannabinol, or one of their aforesaid phe
ratory depression (overdose), in the diagnosis of nar
cotic addiction and in the prophylaxis of narcotic abuse; 60 nolic, pharmacologically active analogues, advanta
geously formulated into a solution, suspension, ointment
and morphine analogues which are agonist-antagonists

pure opioid antagonists (e.g. naloxone and naltrexone)

(e.g. buprenorphine, pentazocine, nalorphine and cy
clazocine), which display varying degrees of morphine

or gel adapted for nasal administration.

'

BRIEF DESCRIPTION OF THE DRAWING
The FIGURE of the drawing is a semi-logarithmic
and which can therefore be used as analgesics as well as 65
plot of mean plasma levels of naloxone after intrave
for the purposes for which the relatively pure antago
nous, nasal and oral administration of a dose of 30 pg of
nists are used. Buprenorphine appears to be a particu

like activity as well as of morphine-antagonist behavior,

larly valuable analogue because of its low physical de

naloxone per rat.

4,464,378
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DETAILED DESCRIPTION OF THE

-continued

INVENTION
The narcotic analgesics, narcotic antagonists and

oxymorphone

narcotic agonist-antagonists intended for use in the 5
compositions and method of the present invention in
clude morphine and pharmacologically active ana
logues thereof having at least one aromatic ring, said
ring bearing at least one free OH group. Particularly

N

/

CH3

signi?cant morphine analogues contemplated by the
present invention include morphine-like analgesics such
as apomorphine, hydromorphone, levorphanol, meto
pon and oxymorphone; and narcotic antagonists and
agonist-antagonists such as buprenorphine, diprenor 15

phine, butorphanol, cyclazocine, pentazocine, phenazo
cine, levallorphan, nalorphine, naloxone, alazocine,

HO

O

buprenorphine

nalbuphine, oxilorphan, nalmexone and naltrexone.
Other analogues contemplated by the invention in

cluded ketobemidone, apocodeine, profadol, cyclor
phan, cyprenorphine, desomorphine, dihydromorphine,

3-hydroxy-N-methylmorphinan,

20

levophenacylmor

phan, metazocine, norlevorphanol, oxymorphone,
phenomorphan, pholcodine and hydroxypethidine. Es
pecially preferred morphine analogues are those having
antagonist or agonist-antagonist properties, especially
naloxone, nalbuphine, naltrexone, buprenorphine and
butorphanol. Any pharmaceutically acceptable form of

25

butorphanol
morphine or of its phenolic analogues can be used, i.e.
30
the free base or a pharmaceutically acceptable acid
addition salt thereof (e. g. naloxone hydrochloride, nal

buphine hydrochloride, nalorphine hydrochloride, na
lorphine hydrobromide, levallorphan tartrate, mor

phinc sulfate, levorphanol tartrate, buprenorphine hy
drochloride, butorphanol tartrate, pentazocine lactate,
pentazocine hydrochloride, phenazocine hydrobro
mide, morphine hydrochloride, profadol hydrochlo

35

ride, etc.); generally, the selected compound is em
ployed in the instant compositions and method in the

HO

pharmaceutically acceptable form which has previously
been found most advantageous for use by injection or

cyclazocine

orally. The structural formulae for representative free

N/CHz-Q

bases encompassed by the present invention are set
forth below:
45

apomorphine
— CH3

CH3
HO

55
HO

pentazocine

OH

CH3

levorphano]
CH3
60

—CH3
CH3
HO
HO

4,464,378

5
-continued

phenazocine

6
-continued

profadol
N

/

OH

CHZCHZ

—CH3
N

10

CH3
HO

nalorphine

These morphine analogues and their salts can be pre
pared by well-known methods. Morphine itself can of

CH2CH=CH2

course be isolated from natural ‘sources and then con

verted, if desired, into a pharmaceutically acceptable

N

acid addition salt. »

The cannabinoids intended for use in the method and

compositions of the present invention include A9-tet
20 rahydrocannabinol (THC) and pharmacologically ac
tivederivatives thereof having at least one free OH
group on an aromatic ring thereof. .A9-Tetrahydrocan
nabinol has the structural formula
HO

~ O

Q“

25

levallorphan

CH;CH=CH2
‘

/

.

-

N

30

Preferred derivatives thereof for use in the present in
35

naloxone

CH2CH=CH2
.

/
N

vention include‘cannabidiol (CBD) and levonantradol.
These compounds can be prepared by known methods
or, in the case of THC and CBD, isolated from natural

‘
sources.

.

'

'

'

In accord with the present invention, morphine, THC

and‘ their pharmacologically active phenolic analogues
can be administered nasally with results considerably

H0

0

nalbuphine

.

\\O

superior to those obtained with oral administration in
terms of enhanced drug bioavailability and minimiza
tion of blood level variations, thus enabling 'use of these
45 drugs at the dosage levels previously possible only by ‘
injection without the disadvantages inherent in subcuta- “
neous, intrasmuscular or intravenous administration. It

would appear that‘ these drugs are rapidly absorbed

N-CH2—<>

from the nasal mucosa into systemic blood without
extensive metabolism in the gastrointestinal tract and
./or extensive ?rst-pass metabolism.
The following study was undertaken to examine the

bioavailability of a representative drug employed in the
method and compositions of the invention, namely nal
55
HQ

0

oxone, administered nasally, in comparison with the

‘bioavailability of that drug when administered orally
and intraveneously.

’ ‘DH

naltrexone

Sprague-Dawley male rats, each weighing about 270
grams, were used in the study. Three groups of three,
rats each were employed, one group for each route of
administration. The rats were anesthetized with pento

barbital (50 mg/kg) prior to administration of the drug.
Naloxone was administered at a dose of 30 lag/rat (~40
pCi/rat) as 3H-naloxone in 0.1 m1 of isotonic saline. For
65

intravenous administration, the drug was injected

' through the femoral vein. For oral (intraduodenal) ad
ministration, the abdomen of ‘ each rat was opened
through a midline incision and the drug was injected

4,464,378
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directly through the duodenum. For nasal administra

TABLE I '

tion, an incision was made in the neck of each rat and
the trachea was cannulated with a polyethylene tube.
Another tube was inserted from the esophagus to the

(PART C)
PLASMA LEVELS OF NALOXONE AFTER ORAL

ADMINISTRATION OF 30 pg/RAT (40 uCi/RAT) OF 3H

5

posterior part of the nasal cavity, and the nasoplantine

NALOXONE IN INDIVIDUAL RATS

Time

was closed with an adhesive agent to prevent drainage
of the drug from the nasal cavity to the mouth. The
drug was then administered to the nasal cavity through
the tube by means of a syringe. Blood was sampled 10

Plasma Level (ng/ml)

(Min.)

periodically from the femoral aorta. Unchanged radi
olabelled naloxone was analyzed according to the pro
cedure described by Fishman et al, J. Pharmacol. Exp.
Ther. 187, 575-580 (1973). The method involved cen
trifugation of the blood and spiking the plasma samples
with cold naloxone. The drug was then extracted from
the plasma with ethyl acetate. The ethyl acetate extract
was then spotted onto thin layer chromatographic
plates and the plates were developed in a 100:60:2 chlo

1

II

III

Mean

SE

1
3

0.22
0.44

0.10
0.15

1.43
0.74

0.25
0.44

0.10
0.30

5
10
20

0.18
0.22
0.19

0.30
0.15
0.03

0.64
0.64
0.25

0.37
0.34
0.16

0.24
0.15
0.11

30

0.28

0.10

0.17 '

0.18

0.09

45
60
90

0.13
0.10
0.04

0.05
0.02
0.03

0.16
0.14
0. 12

0.11
0.09
0.06

0.06
0.06
0.05

120 ‘

0.03

0.06

0.10

0.06

0.04

180

0.03

0.02

0.07

0.04

0.03

TABLE 11

roform-methanol-acetic acid system (parts by volume).

AREA UNDER THE BLOOD LEVEL CURVE VALUES

(AUC ‘0) FOR INDIVIDUAL RATS FROM THE THREE

The zone corresponding to free naloxone visualized by
ultraviolet absorption was removed and the radioactiv

ROUTES OF ADMINISTRATION OF NALOXONE AND
HALF-LIVES 0F ELIMINATION OF NALOXONE
FOLLOWING INTRAVENOUS AND NASAL

ity counted.

ADMINISTRATION

TABLE I below shows the individual plasma level 25
data of naloxone from intravenous (PART A), nasal
IV
Nasal

(PART B) and oral (PART C) routes, while the ?gure
of drawing shows the mean plasma levels of naloxone

Oral

1

11

111

1269.7
1904.2

1540.5
1336.2

1685.8
1312.0

19.1

11.3

35.5

Mean

SE

1498.7 121.9
1517.5 193.5
22.0

7.1

11
59.2 min.
52.1 min.
-

for the different routes of administration. TABLE II 30 BIOAVAILABILITY CALCULATIONS:
AUC nasal
below shows the area under the curve values (AUC 0)
W x 100 = 1.013 X 100 = 101.3%
for the individual rats for each of the three routes of
AM >< 100 = 0.015 x 100 = 1.5%
AUC iv

administration, the bioavailability calculated for the
nasal and oral routes, and the half-lives of elimination of

the drug after intravenous and nasal administration.

35

TABLE I

naloxone via the nasal route of administration was as

Plasma Level (nglml!
Time
(Min.)

1

II

III

effective as via the intravenous route. On the othe1
Mean

hand, oral administration of 30 pg of naloxone resulted
in bioavailability equal to only 1.5% that of the same
dose given intravenously. Also from TABLE II, it can

SE

PLASMA LEVELS OF NALOXONE AFTER INTRA

VENOUS ADMINISTRATION OF 30 lag/RAT (4O “Ci/RAT)
OF 3I*I—NALOXONE IN INDIVIDUAL RATS
1
3
5
10
20
30
45
60
90
120
180

101.65
52.28
31.38
15.60
10.27
7.28
5.47
4.87
3.01
2.15
1.25

91.45
44.00
33.03
16.92
11.44
9.16
7.98
5.82
4.63
3.87
1.77

138.57
77.77
47.93
26.34
13.01
8.59
6.77
5.54
4.23
2.57
1.40

110.56
58.02
37.45
19.62
11.57
8.34
6.74
5.41
3.96
2.86
1.47

14.31
10.16
5.26
3.38
0.79
0.56
0.72
0.28
0.49
0.52
0.15

PLASMA LEVELS OF NALOXONE AFTER NASAL

ADMINISTRATION OF 30 ug/RAT (40 pCi/RAT) OF
3I-I—NALOXONI£ IN INDIVIDUAL RATS
1
3
5
10
20
30
45
60
90

36.20
41.21
54.45
45.30
22.73
13.46
9.36
8.26
4.79

12.71
30.85
33.41
31.53
17.68
11.83
7.95
5.98
3.16

120

3.65

180

1.95

It can be seen from TABLE II that the areas undei

the curve following intravenous and nasal administra‘
tion were not signi?cantly different, i.e. absorption 01

20.97
42.80
44.15
31.02
17.99
10.79
6.56
4.98
2.80

23.29
38.29
44.00
35.95
19.47
12.03
7.96
6.41
3.58

6.88
3.75
6.07
4.68
1.63
0.78
0.81
0.97
0.61

2.29

1.84

2.59

0.54 '

1.22

1.10

1.42

0.27

be seen that the nasal bioavailability of naloxone was

nearly 70 times greater than the oral bioavailability.
45

It also can be seen from TABLE I and the FIGURE

of drawing that naloxone was very rapidly absorbed
from the nasal mucosa; thus, at the 30 1.1g dosage level,
the peak plasma level was attained in about 5 minutes
after instillation of the nose drops. Further, the half-life
50 of elimination of the drug after nasal administration was
found to be comparable to its half-life following intrave
nous nasal administration.

The study described above indicates that naloxone is
rapidly absorbed from the nasal mucosa into the sys
55 temic circulation without extensive intestinal or ?rst
pass metabolism. It is further apparent from this study

that the bioavailability of naloxone when administered
nasally is equivalent to the bioavailability of the drug
when administered intravenously and vastly superior to
its bioavailability by the oral route. As the phenolic
hydroxyl group in naloxone is believed to be responsi
ble for the extensive metabolism seen when the drug is

administered orally and, consequently, for the drug’s
poor oral bioavailability, it follows that similar im
65 provement in bioavailability for nasal versus oral ad
ministration will be observed in the case of the other
phenolic drugs intended for use in the method and com

positions of the present invention.

9
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Any of the selected drugs intended for use in the
present invention, i.e. morphine, THC or one of their

pharmacologically active phenolic analogues, can be
administered nasally to warm-blooded animals, conve
niently by formulation into a nasal dosage form com

prising the desired drug, in a therapeutically effective
amount (i.e., depending on the selected drug, an anal
gesically effective amount, an antiemetic effective
amount, an amount effective to antagonize the effects of

a narcotic agent, etc.), together with a nontoxic phar

maceutically acceptable nasal carrier therefor. This

10

EXAMPLE 1
l Gram of naloxone hydrochloride is dissolved in 80
ml of distilled water and the pH of the resultant solution
is adjusted to 7.4 with dilute sodium hydroxide solution.
A quantity of water sufficient to bring the total volume
to 100 ml is then added and suf?cient sodium chloride

(or other appropriate salt) is added to adjust the solution
to isotonicity. The solution is then sterilized by being
passed through a 0.2 micron Millipore ?lter. The ?nal
composition contains 1 mg of naloxone hydrochloride

type of composition can be used in the treatment of any
per 0.1 mlof solution.
.
of the variety of conditions which are responsive to
The above procedure is repeated using 1 gram of
treatment with the selected drug itself by other routes
levallorphan tartrate in place of the naloxone hydro
of administration.
15 chloride. The resultant composition contains 1 mg of

As indicated earlier, in the compositions of the inven
tion, the drug can be employed in the form of the free
base or, in the case of morphine and its analogues, in the

form of a pharmaceutically acceptable salt thereof.

lavallorphan tartrate per 0.1 ml of solution.
Repetition of the procedure of the ?rst paragraph of

this example using 5 grams of apomorphine hydrochlo
ride, 3 grams of hydromorphone hydrochloride, 4

Suitable nontoxic pharmaceutically acceptable nasal 20 grams of metopon hydrochloride, 1.5 grams of oxymor
phone hydrochloride, 0.6 grams of buprenorphine hy

carriers will be apparent to those skilled in the‘ art of

nasal pharmaceutical formulations. For those not skilled

drochloride, 2 grams of butorphanol tartrate, 3 grams of

in the art, reference is made to the text entitled “REM

pentazocine hydrochloride, 3 grams of phenazocine
hydrobromide or 5 grams of nalorphine hydrochloride

INGTON’s PHARMACEUTICAL SCIENCES”,
14th, edition, 1970. Obviously, the choice of suitable
carriers will depend on the exact nature of the particu
lar nasal dosage ‘form desired, e.g., whether the drug is

in place of the naloxone hydrochloride affords a nasal

composition containing, respectively, 5 mg of apomor
phine hydrochloride, 3 mg of hydromorphone hydro

to be formulated into a nasal solution (for use as drops

chloride, 4 -mg of metopon hydrochloride, 1.5 mg of

or as a spray), a nasal suspension, a nasal ointment or a

oxymorphone hydrochloride, 0.6 mg of buprenorphine

nasal gel. Preferred nasal dosage forms are solutions, 30 hydrochloride, 2 mg of butorphanol tartrate, 3 mg of
suspensions and gels, which contain a major amount of
pentazocine hydrochloride, 3 mg of phenazocine hy
water (preferably puri?ed water) in addition to the
drobromide, or 5 mg of nalorphine hydrochloride, per
active ingredient. Minor amounts of other ingredients
0.1- ml of solution.
such'as pH adjusters (e.g., a base such as NaOH), emul
EXAMPLE 2
si?ers or dispersing agents, buffering agents, preserva 35
tives, wetting agents and jelling agents (e.g., methylcel
l5 Grams of nalbuphine hydrochloride are combined
lulose) may also be present. Most preferably, the nasal
with 80 ml of distilled water and the pH is adjusted to
composition is isotonic,’ is. it has the same osmotic
4.5 with dilute sodium hydroxide solution. A quantity of
pressure as blood serum. If desired, sustained release
water suf?cient to bring the total volume to 100 ml is
nasal compositions, e.g. sustained release gels, can be 40 then added and suf?cient sodium chloride is added to
readily prepared, preferably by employing the desired
adjust the solution to isotonicity. The solution is then
drug in oneof itsi ‘relatively insoluble forms, such as the
sterilized by being passed through a 0.2 micron Mil
free base or anfinsoluble 'salt. In the case of morphine
lipore ?lter. The resultant composition contains 15 mg
and its analogues§‘when the free base is not suf?ciently
of nalbuphine hydrochloride per 0.1 ml.
insoluble for sustained release compositions, or when a 45
The procedure described above is substantially re
more highly insoluble form is desired, a long chain
peated, except that 15 grams of morphine sulfate are
carboxylic acid salt of the desired drug can be'conve
used in place of the nalbuphine hydrochloride, afford
niently employed. The carboxylic acid portion of the
ing a nasal composition containing 15 mg of morphine

salt preferably contains 10 to 20 carbon atoms. Such

“salts (e.g. stearates, palmitates etc.) can be readily syn 50

thesized, for example, by dissolving the hydrochloride
salt of the drug in water, then adding the alkali metal
salt of the desired long chain carboxylic acid (e.g. so
dium stearate). The corresponding long chain carbox
ylic acid salt of the drug which precipitates out of the

solution is removed by ?ltration. Alternatively, equimo
lar amounts of the free base of the drug and the long
chain carboxylic acid are combined in methanol. That
mixture is then added to a small volume of water, caus

sulfate per 0.1 ml. '

Repetitionv of the procedure of the ?rst paragraph of
this example using 20 grams of pentazocine lactate in
place of the nalbuphine hydrochloride affords a nasal
composition containing 20 mg of pentazocine lactate
per ‘0.1 ml.
EXAMPLE 3
l Gram of naltrexone is dissolved in 80 ml of isotonic
saline solution and the pH of the resultant solution is

adjusted to 7.0-7.2 with dilute hydrochloric acid. A
ing the desired salt (e.g. stearate) of the drug to precipi 60 quantity of isotonic saline suf?cient to bring the total
tate out.

Examples of the preparation of typical nasal composi

volume to 100 ml is then added, and the solution, is
sterilized by being passed through a 0.2 micron Mil
lipore ?lter. The resultant composition contains 1 mg of
naltrexone per 0.1 ml.

tions containing selected drugs are set forth below.
However, it is to be understood that these examples are
given by way of illustration only and are not to be con 65 Repetition of the foregoing procedure utilizing 0.5
strued as limiting the invention either in spirit or in
gram of levonantradol in place of the naltrexone affords
scope as many modi?cations both in materials and in
a nasal composition containing 0.5 mg of levonantradol
methods will be apparent to those skilled in the art.
per 0.1 ml.

4,464,378
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The procedure of the ?rst paragraph of this example
is substantially repeated, save that 4 grams of butor
phanol are employed in place of the naltrexone, to af
ford a nasal composition containing 4 mg of butor

COMPOSITION B

Ingredient
nalorphine hydrobromide

phanol per 0.1 ml.

Tween 80

Substitution of 2 grams of cyclazocine for the naltrex
one used in the ?rst paragraph of this example and

substantial repetition of the procedure there detailed
afford a nasal composition containing 2 mg of cyclazo
cine per 0.1 ml.

Amount
500 mg
3 m8

methylcellulose
water, puri?ed

30 mg
10 ml

10
COMPOSITION C

EXAMPLE 4

Ingredient
buprenorphine hydrochloride

80 Grams of water are heated to 80° C. and 3.0 grams

of Methocel are added, with stirring. The resultant

Amount
100 mg

Tween 80

2 mg

methylcellulose
water, puri?ed

mixture is allowed to stand at room temperature for 3
hours. Then, 1.5 grams of naloxone stearate are sus

20 mg
10 ml

pended in 20 grams of water, that suspension is added to

Naturally, the therapeutic dosage range for nasal
the gel and thoroughly mixed, and the resultant viscous
solution or gel is adjusted to isotonicity with sodium 20 administration of the drugs according to the present
invention will vary with the size of the patient, the
chloride. The sustained release composition thus ob
condition for which the drug is administered and the
tained contains 1.5 mg of naloxone stearate per 0.1 ml.

particular drug employed. Generally, the daily dosage

The above procedure is substantially repeated, except
that 2.0 rather than 3.0 grams of Methocel are em

will approximate the amounts previously employed for

ployed, and 1.5 grams of naltrexone myristate are substi

IV, IM or SC administration of the particular drug
involved. Thus, a typical dose of buprenorphine would

tuted for the naloxone stearate. The sustained release
composition prepared in this manner contains 1.5 mg of

be 4-8 mg per day as a maintenance dose in the treat

ment of narcotic addicts. The quantity of nasal dosage

naltrexone myristate per 0.1 ml.

form needed to deliver the desired dose will of course

Repetition of the procedure of the ?rst paragraph of
this example, but using 20 grams of nalbuphine palmi

depend on the concentration of drug in the composi
tion. The volume of solution or gel which would be

tate in place of the naloxone stearate, affords a sustained

needed to deliver the daily dose of buprenorphine speci
release composition containing 20 mg of nalbuphine
?ed above would be 0.1 to 0.2 ml of 4% solution or gel.
palmitate per 0.1 ml.
While the invention has been described in terms of
The procedure of the ?rst paragraph of this example
is substantially repeated, except that 3 grams of levor 35 various preferred embodiments, the skilled artisan will
appreciate that various modi?cations, substitutions,
phanol stearate are employed in place of the naloxone
stearate. The resultant sustained release composition
contains 3 mg of levorphanol stearate per 0.1 ml.
Substitution of 4 grams of buprenorphine stearate for
the naloxone stearate used in the ?rst paragraph of this 40

example and substantial repetition of the procedure
there detailed afford a sustained release composition
containing 4 mg of buprenorphine stearate per 0.1 ml.
In a similar manner, repetition of the procedure of the

?rst paragraph of this example, but using 2.5 grams of

omissions and additions may be made without departing
from the spirit thereof. Accordingly, it is intended that
the scope of the present invention be limited solely by
the scope of the following claims.
What is claimed is:
1. A method for eliciting an analgesic or narcotic
antagonist response in a warm-blooded animal, which

comprises nasally administering to said animal:
45

butorphanol palmitate, 3.5 grams of pentazocine myris

(a) to elicit an analgesic response, an analgesically

effective amount of morphine, hydromorphone,

metopon, oxymorphone, desomorphine, dihydro
morphine, levorphanol, cyclazocine, phenazocine,

tate, 10 grams of THC, 20 grams of GED or 1 gram of
levonantradol in place of the naloxone stearate affords a

levallorphan,

sustained release composition containing, respectively,

3-hydroxy-N-methylmorphinan,

levophenacylmorphan,

2.5 mg of butorphanol palmitate, 3.5 mg of pentazocine

metazocine,

norlevor

phanol, phenomorphan, nalorphine, nalbuphine,

myristate, 10 mg of THC, 20 mg of CBD or 1 mg of
levonantradol, per 0.1 ml.

buprenorphine, butorphanol or pentazocine, or a

nontoxic pharmaceutically acceptable acid addi

EXAMPLE 5
The following are illustrative aqueous solutions of 55
selected drugs suitable for use as nasal drops or nasal
spray. In each case, the pH of the ?nal composition is
adjusted to 7.4. If desired, the solutions are adjusted to

isotonicity.

tion salt thereof; or

.

(b) to elicit a narcotic antagonist response, a narcotic

antagonist effective amount of naloxone, naltrex

one, diprenorphine, nalmexone, cyprenorphine,

levallorphan, alazocine, oxilorphan, cyclorphan,
nalorphine, nalbuphine, buprenorphine, butor
phanol, cyclazocine or pentazocine, or a nontoxic

pharmaceutically acceptable acid addition salt
thereof.

COMPOSITION A

Ingredient
nalbuphine hydrochloride
Tween 80

methylcellulose
water, puri?ed

2. A method according to claim 1 for eliciting a nar
cotic antagonist response in a warm-blooded animal,

Amount
1000 mg
4 mg

40 mg
10 ml

65

which comprises nasally administering to said animal a
narcotic antagonist effective amount of naxolone, nal

trexone, diprenorphine, nalmexone, cyprenorphine,
levallorphan, alazocine, oxilorphan, cyclorphan, nalor
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phine, nalbuphine, buprenorphine, butorphanol, cyclaz

14

ocine or pentazocine, or a nontoxic pharmaceutically

18. The method according to claim. 17 wherein the
compound administered is hydromorphone, metopon or

acceptable acid addition salt thereof.
3. The method according to claim 2 wherein the
compound administered is naloxone, naltrexone, nalor

able acid addition salt thereof.

oxymorphone, or a nontoxic pharmaceutically accept
‘

19. The method according to claim 15 wherein the
compound administered is in the form of a long chain

phine, nalbuphine, buprenorphine, diprenorphine, nal
mexone or cyprenorphine, or a nontoxic pharmaceuti

carboxylic acid salt, the carboxylic acid portion of the

cally acceptable acid addition salt thereof.

salt containing from 10 to 20 carbon atoms.
20. A method according to claim 2 wherein the com

4. The method according to claim 2 wherein the
compound administered is in the form of a long-chain

pound administered is butorphanol, pentazocine, cy

carboxylic acid salt, the carboxylic acid portion of the

clazocine or oxilorphan, or a nontoxic pharmaceutically

salt containing from 10 to 20 carbon atoms.
5. The method according to claim 4 wherein the long
chain carboxylic acid salt is a stearate, palmitate or

acceptable acid addition salt thereof. .

myristate.

,

15

‘

I

21. The method according to claim 20 wherein the
compound administered is butorphanol or a nontoxic

pharmaceutically acceptable acid addition salt thereof.

22. A method according to claim 11 wherein the
6. The method according to claim 3 wherein the
compound administered is butorphanol, cyclazocine or
compoundadministered is naloxone or a nontoxic phar
pentazocine, or a nontoxic pharmaceutically acceptable
maceutically acceptable acid addition salt thereof.
acid addition salt thereof.
7. The method according to claim 3 wherein the
20
23. The method according to claim 17 wherein the
compound administered is naltrexone or a nontoxic
compound administered is levorphanol or a nontoxic
pharmaceutically acceptable acid addition salt thereof.
pharmaceutically acceptable acid addition salt thereof.
8. The method according to claim 3 wherein the
24. The method according to claim 1 wherein the
compound administered is nalorphine or a nontoxic

compound administered is morphine, oxymorphone,
buprenorphine, naloxone, nalorphine, nalbuphine, nal

pharmaceutically acceptable acid addition salt thereof.
9. The method according to claim .3 wherein the
compound administered is nalbuphine or a nontoxic

,trexone, hydromorphone, metopon, nalmexone, cy
prenorphine or diprenorphine, or a nontoxic pharma

pharmaceutically acceptable acid addition salt thereof.

ceutically acceptable acid addition salt thereof.

10. The methodv according to claim 3 wherein the

25. The method according to claim 24 wherein the
compound administered is buprenorphine or a nontoxic 30
compound is in the form of a long-chain carboxylic acid

pharmaceutically acceptable acid addition salt thereof.
salt, the carboxylic acid portion of the salt containing
11. A method according‘to claim 1 for. eliciting an
from 10 to 20 carbon atoms.
analgesic response in, a warm-blooded animal which
26. The method according to claim 25 wherein the
comprises nasally administering to said animal 'an anal
long-chain carboxylic acid salt is a stearate, palmitate or
gesically effective'amount of ~ nalorphine, nalbuphine, 35 , I myristate.
buprenorphine, butorphanol, cyclazocine, levallorpha'n
27. The method according to claim l-wherein the
or pentazocine, or a-nontoxic pharmaceutically accept _' compound administered is levorphanol, cyclazocine,
able acid addition salt thereof.

'

phenazocine, butorphanol, pentazocine or oxilorphan,

12. The method according to claim 11 wherein the

or a nontoxic pharmaceutically acceptable acid addition

compound administered is in the form of a long chain

salt'thereof.
28. The method according to claim 27 wherein the
compound is in the form of a long-chain carboxylic acid
salt, the carboxylic acid portion of the salt containing

carboxylic acid salt, the carboxylic acid portion of the
salt containing from 10 to 20 carbon atoms.
13. The method according to claim‘ 12 wherein the
long chain carboxylic acid salt is a stearate, palmitate or
myristate.

from 10 to 20 carbon atoms.

'

_

29. The method according to claim 28 wherein the
long-chain carboxylic acid salt is a stearate, palmitate or

14. The method according to claim 11 wherein the
compound administered is buprenorphine or a nontoxic

myristate.

pharmaceutically acceptable acid addition salt thereof.

30. A pharmaceutically acceptable nasal dosage form

15. A method according to claim 1 for eliciting an
for eliciting an analgesic response in a warm-blooded
analgesic response in a warm-blooded animal, which 50 animal, which comprises (i) an analgesically effective
comprises nasally administering to said animal an anal
amount of morphine, hydromorphone, metopon, oxy

gesically effective amount of morphine, hydromor

phone, metopon, oxymorphone, desomorphine, dihy
dromorphine, levorphanol, phenazocine, 3-hydroxy-N
methylrnorphinan, levophenacylmorphan, metazocine,
norlevorphanol or phenormorphan, or a nontoxic phar

maceutically acceptable acid addition salt thereof.
16. The method according to claim 15 wherein mor
phine is administered, in the form of the free base or a

morphone, desomorphine, dihydromorphine, levorpha
nol, cyclazocine, phenazocine, 3-hydroxy-N-methyl
morphinan, levophenacylmorphan, metazocine, nor

55

levorphanol, phenomorphan, nalorphine, nalbuphine,
buprenorphine, butorphanol, levallorphan or pentazo
cine, or a nontoxic pharmaceutically acceptable acid
addition salt thereof, and (ii) a nontoxic pharmaceuti

cally acceptable nasal carrier therefor, said nasal dosage
nontoxic pharmaceutically acceptable acid addition salt 60 form comprising a nasal ointment or a nasal gel.
thereof.
31. A dosage form according to claim 30, said dosage
17. The method according to claim 15 wherein hy
form comprising a nasal ointment.

dromorphone, metopon, oxymorphone, desomorphine,
dihydromorphine, levorphanol, phenazocine, 3

32. A dosage form according to claim 30, said dosage
form comprising a nasal gel.
hydroxy-N-methylmorphinan, levophenacylmorphan, 65 33. A dosage form according to claim 32, said dosage
metazocine, norlevorphanol or phenomorphan is ad
form comprising a sustained release nasal gel.
34. A dosage form according to claim 30, wherein (i)
ministered, in the form of the free base or a nontoxic
comprises an analgesically effective amount of mor
pharmaceutically acceptable acid addition salt thereof.

15
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butorphanol, pentazocine, naloxone, naltrexone, dipren
orphine, nalmexone, cyprenorphine, levallorphan,

phine or buprenorphine, or of a nontoxic pharmaceuti

cally acceptable acid addition salt of morphine or bu

prenorphine.

alazocine, oxilorphan or cyclorphan, and (ii) a nontoxic

35. A dosage form according to claim 30, wherein the
compound administered is in the form of a long chain
carboxylic acid salt, the carboxylic acid portion of the

pharmaceutically acceptable nasal carrier therefor.
43. A dosage form according to claim 42, wherein (i)
comprises a systemically therapeutically effective

salt containing from 10 to 20 carbon atoms.

amount of a long chain carboxylic acid salt of naloxone,
naltrexone, nalorphine, nalbuphine or buprenorphine.

36. A pharmaceutically acceptable nasal dosage form
for eliciting a narcotic antagonist response in a warm

44. A dosage form according to claim 42, wherein the

blooded animal, which comprises (i) a narcotic antago
nist effective amount of naloxone, naltrexone, diprenor

carboxylic acid portion of said salt contains 10 to 20
carbon atoms.

phine, nalmexone, cyprenorphine, levallorphan, alazo
cine, oxilorphan, cyclorphan, nalorphine, nalbuphine,

said salt is a stearate, palmitate or myristate.

45. A dosage form according to claim 44, wherein

buprenorphine, butorphanol, cyclazocine or pentazo

46. A dosage form according to claim 42, said dosage
form comprising a nasal solution, nasal suspension, nasal

cine, or a nontoxic pharmaceutically acceptable acid
addition salt thereof, and (ii) a nontoxic pharmaceuti

ointment or nasal gel.

cally acceptable nasal carrier therefor, said nasal dosage

47. A dosage form according to claim 42, wherein (i)

form comprising a nasal ointment or a nasal gel.

comprises a systemically therapeutically effective

37. A dosage form according to claim 36, said dosage
form comprising a nasal ointment.

amount of a long chain carboxylic acid salt of levorpha
20

nol, cyclazocine, phenazocine, butorphanol, pentazo

38. A dosage form according to claim 36, said dosage
cine or oxilorphan.
form comprising a nasal gel.
48. A method for eliciting an analgesic response in a
39. A dosage form according to claim 38, said dosage
warm-blooded animal, which comprises nasally admin
form comprising a sustained release nasal gel.
istering to said animal an analgesically effective amount
40. A dosage form according to claim 36, wherein (i) 25 of a pharmaceutically acceptable nasal dosage form as
comprises a narcotic antagonist effective amount of
claimed in claim 30.
naloxone, naltrexone, nalorphine, nalbuphine or bu
49. A method for eliciting a narcotic antagonist re
prenorphine, or of a nontoxic pharmaceutically accept
sponse in a warm-blooded animal, which comprises
able acid addition salt of naloxone, naltrexone, nalor
nasally administering to said animal a narcotic antago
phine, nalbuphine or buprenorphine.
30 nist effective amount of a pharmaceutically acceptable
41. A dosage form according to claim 36, wherein the
nasal dosage form as claimed in claim 36.
compound administered is in the form of a long chain
50. A dosage form according to claim 36, wherein (i)
carboxylic acid salt, the carboxylic acid portion of the
comprises a narcotic antagonist effective amount of
salt containing from 10 to 20 carbon atoms.
butorphanol, pentazocine, cyclazocine or oxilorphan,
42. A pharmaceutically acceptable sustained release
or of a nontoxic pharmaceutically acceptable acid addi
nasal dosage form for nasally delivering systemic thera~
tion salt of butorphanol, pentazocine, cyclazocine or
peutic levels of drug to a warm~blooded animal which

oxilorphan.

comprises (i) a systemically therapeutically effective
amount of a long chain carboxylic acid salt of morphine,

hydromorphone, metopon, oxymorphone, desomor

,

51. A dosage form according to claim 30, wherein (i)
comprises an analgesically effective amount of levor
40

phine, dihydromorphine, levorphanol, cyclazocine,
phenazocine, 3-hydroxy-N-methylmorphinan, levo~
phenacylmorphan, metazocine, norlevorphanol, pheno
morphan, nalorphine, nalbuphine, buprenorphine,

phanol, cyclazocine, phenazocine, butorphanol or pen
tazocine, or of a nontoxic pharmaceutically acceptable

acid addition salt of levorphanol, cyclazocine, phenazo
cine, butorphanol or pentazocine.
*
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